2016
DOI: 10.1016/j.cct.2015.11.011
|View full text |Cite
|
Sign up to set email alerts
|

Cost-benefit assessment of using electronic health records data for clinical research versus current practices: Contribution of the Electronic Health Records for Clinical Research (EHR4CR) European Project

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
39
0
3

Year Published

2016
2016
2021
2021

Publication Types

Select...
7
1

Relationship

4
4

Authors

Journals

citations
Cited by 51 publications
(43 citation statements)
references
References 15 publications
1
39
0
3
Order By: Relevance
“…In view of escalating R&D costs [1,2], the biopharmaceutical industry is exploring new ways to enhance R&D platforms and to reduce costs. By enabling the reuse of EHR health data for clinical research, the EHR4CR innovative platform provides a new powerful tool to increase the efficiency of clinical research processes [5,[8][9][10][11]. Importantly, by using advanced interoperable electronic data exchange systems, the EHR4CR platform performs protocol feasibility assessment in a seamless manner, simultaneously in multiple countries, across various hospitals, in a matter of minutes rather than the days or weeks under current conditions.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…In view of escalating R&D costs [1,2], the biopharmaceutical industry is exploring new ways to enhance R&D platforms and to reduce costs. By enabling the reuse of EHR health data for clinical research, the EHR4CR innovative platform provides a new powerful tool to increase the efficiency of clinical research processes [5,[8][9][10][11]. Importantly, by using advanced interoperable electronic data exchange systems, the EHR4CR platform performs protocol feasibility assessment in a seamless manner, simultaneously in multiple countries, across various hospitals, in a matter of minutes rather than the days or weeks under current conditions.…”
Section: Resultsmentioning
confidence: 99%
“…A recent cost-benefit assessment (CBA) conducted by Beresniak et al has assessed the value of the EHR4CR platform compared to current practices for conducting Phase II and III clinical trials in oncology (as the reference case) [11]. This study has established that the EHR4CR platform provides significant added value to clinical trial sponsors for enabling the trustworthy reuse of EHR hospital-based clinical data for clinical research, in compliance with regulatory, legal, ethical and data privacy protection requirements.…”
Section: Resultsmentioning
confidence: 99%
“…As the pharmaceutical industry is remodelling its R&D platforms to enhance its value chain, reduce costs and improve efficiency [3,[49][50][51][52][53], EHR4CR solutions promise to transform the clinical research landscape by enhancing and speeding up existing clinical research processes. Using a scalable approach, the deployment of EHR-enabled solutions for research will generate new business opportunities with significant growth potential for all stakeholders involved, as well as added value for clinical trial sponsors [52,53], for the benefit of patients, health systems, and society [2].…”
Section: Discussionmentioning
confidence: 99%
“…In particular, a cost-benefit assessment [52,53] and a budget impact analysis [54] were carried out from the perspective of primary sponsors of clinical trials, establishing the added value and the financial impact of using EHR4CR solutions compared to current practices. While these assessments were highly conclusive, they are based on validated assumptions, including market readiness in Europe and a swift adoption of EHR4CR…”
Section: Delivering Valuementioning
confidence: 99%
“…There is now also growing evidence that the reuse of EHRs in this way is cost-beneficial to the pharma industry [8] .…”
Section: Introductionmentioning
confidence: 99%